Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 16/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 10/20 | 0.45 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 4/20 | 0.40 |
| ▸ | CA2 | P00918 | 4/20 | 0.40 |
| ▸ | CA9 | Q16790 | 4/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20042423 | 0.84 | CA9 (0.47) | PTGS2PTGS1CA1CA2CA9 | |
| SCHEMBL20042430 | 0.82 | CA9 (0.47) | PTGS2PTGS1CA1CA2CA9 | |
| SCHEMBL20042422 | 0.82 | PTGS2 (0.48) | PTGS2PTGS1CA1CA2CA9 | |
| SCHEMBL20042435 | 0.82 | PTGS2 (0.58) | PTGS2PTGS1CA1CA2CA9 | |
| SCHEMBL20042412 | 0.78 | PTGS2 (0.57) | PTGS2PTGS1ALOX5CA1CA2 | |
| SCHEMBL20042421 | 0.76 | PTGS2 (0.52) | PTGS2PTGS1ALOX5CA1CA2 | |
| SCHEMBL30194239 | 0.75 | PTGS2 (0.69) | PTGS2PTGS1ALOX5CA1CA2 | |
| SCHEMBL20042437 | 0.75 | PTGS2 (0.54) | PTGS2PTGS1ALOX5CA1CA2 | |
| SCHEMBL20042414 | 0.75 | PTGS2 (0.56) | PTGS2PTGS1ALOX5CA1CA2 | |
| SCHEMBL20042420 | 0.75 | PTGS2 (0.56) | PTGS2PTGS1ALOX5CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180098965-A1 | LOCALLY BIOAVAILABLE DRUGS | UNIVERSITY OF HOUSTON SYSTEM (US) | 2018-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180098965-A1 | LOCALLY BIOAVAILABLE DRUGS | ABCG2, FABP1, FABP2 | PTGS2 3366/4885PTGS1 3087/4885ALOX5 3754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.